Related references
Note: Only part of the references are listed.Identification and characterization of DNAzymes targeting DNA methyltransferase I for suppressing bladder cancer proliferation
Xiangbo Wang et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2015)
Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD® immunomodulatory drug pomalidomide
Deepika S. Das et al.
BRITISH JOURNAL OF HAEMATOLOGY (2015)
Safety and activity of RRx-001 in patients with advanced cancer: a first-in-human, open-label, dose-escalation phase 1 study
Tony Reid et al.
LANCET ONCOLOGY (2015)
Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells
A. Ray et al.
LEUKEMIA (2015)
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma
Francesca Cottini et al.
CANCER DISCOVERY (2015)
Nrf2 activity as a potential biomarker for the pan-epigenetic anticancer agent, RRx-001
Shoucheng Ning et al.
ONCOTARGET (2015)
NO to cancer: The complex and multifaceted role of nitric oxide and the epigenetic nitric oxide donor, RRx-001
Jan Scicinski et al.
REDOX BIOLOGY (2015)
Nitric oxide: Protein tyrosine phosphorylation and protein S-nitrosylation in cancer
Hugo P. Monteiro et al.
BIOMEDICAL JOURNAL (2015)
STRING v10: protein-protein interaction networks, integrated over the tree of life
Damian Szklarczyk et al.
NUCLEIC ACIDS RESEARCH (2015)
Episensitization: Therapeutic Tumor Resensitization by Epigenetic Agents: A Review and Reassessment
Bryan Oronsky et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2014)
A novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced myeloma cell growth and enhance cytotoxicity of bortezomib
A. Ray et al.
LEUKEMIA (2014)
Rewriting the Epigenetic Code for Tumor Resensitization: A Review
Bryan Oronsky et al.
TRANSLATIONAL ONCOLOGY (2014)
The role of epigenetics in the biology of multiple myeloma
K. Dimopoulos et al.
BLOOD CANCER JOURNAL (2014)
Acute Depletion Redefines the Division of Labor among DNA Methyltransferases in Methylating the Human Genome
Rochelle L. Tiedemann et al.
CELL REPORTS (2014)
New Nucleophilic Mechanisms of Ros-Dependent Epigenetic Modifications: Comparison of Aging and Cancer
Igor Afanas'ev
AGING AND DISEASE (2014)
Global methylation analysis identifies prognostically important epigenetically inactivated tumor suppressor genes in multiple myeloma
Martin F. Kaiser et al.
BLOOD (2013)
Myeloma Is Characterized by Stage-Specific Alterations in DNA Methylation That Occur Early during Myelomagenesis
Christoph J. Heuck et al.
JOURNAL OF IMMUNOLOGY (2013)
Epigenetic Modulating Agents as a New Therapeutic Approach in Multiple Myeloma
Ken Maes et al.
Cancers (2013)
Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features
Abdel Kareem Azab et al.
BLOOD (2012)
A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance
Dharminder Chauhan et al.
CANCER CELL (2012)
Dinitroazetidines Are a Novel Class of Anticancer Agents and Hypoxia-Activated Radiation Sensitizers Developed from Highly Energetic Materials
Shoucheng Ning et al.
CANCER RESEARCH (2012)
Understanding the hypoxic niche of multiple myeloma: therapeutic implications and contributions of mouse models
Jinsong Hu et al.
DISEASE MODELS & MECHANISMS (2012)
Small Molecule Modulators of Keap1-Nrf2-ARE Pathway as Potential Preventive and Therapeutic Agents
Sadagopan Magesh et al.
MEDICINAL RESEARCH REVIEWS (2012)
DNA damage induces reactive oxygen species generation through the H2AX-Nox1/Rac1 pathway
M. A. Kang et al.
CELL DEATH & DISEASE (2012)
Preclinical Evaluation of the Metabolism and Disposition of RRx-001, a Novel Investigative Anticancer Agent
Jan Scicinski et al.
DRUG METABOLISM AND DISPOSITION (2012)
Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma
Brian A. Walker et al.
BLOOD (2011)
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3
Meletios Dimopoulos et al.
BLOOD (2011)
Oncogenomics to Target Myeloma in the Bone Marrow Microenvironment
Kenneth C. Anderson
CLINICAL CANCER RESEARCH (2011)
Maintenance of DNA methylation Dnmt3b joins the dance
Emma L. Walton et al.
EPIGENETICS (2011)
The USP7/Dnmt1 complex stimulates the DNA methylation activity of Dnmt1 and regulates the stability of UHRF1
Max Felle et al.
NUCLEIC ACIDS RESEARCH (2011)
Angiogenesis and Multiple Myeloma
Nicola Giuliani et al.
CANCER MICROENVIRONMENT (2011)
Combination of novel proteasome inhibitor NPI-0052 and lenalidomide trigger in vitro and in vivo synergistic cytotoxicity in multiple myeloma
Dharminder Chauhan et al.
BLOOD (2010)
Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
R. Scatena et al.
CURRENT MEDICINAL CHEMISTRY (2010)
Low bone marrow oxygen tension and hypoxia-inducible factor-1α overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138+ cells
S. Colla et al.
LEUKEMIA (2010)
DNMT1 Stability Is Regulated by Proteins Coordinating Deubiquitination and Acetylation-Driven Ubiquitination
Zhanwen Du et al.
SCIENCE SIGNALING (2010)
Functional Interaction of Plasmacytoid Dendritic Cells with Multiple Myeloma Cells: A Therapeutic Target
Dharminder Chauhan et al.
CANCER CELL (2009)
Differential repetitive DNA methylation in multiple myeloma molecular subgroups
Valentina Bollati et al.
CARCINOGENESIS (2009)
TGFβR2 aberrant methylation is a potential prognostic marker and therapeutic target in multiple myeloma
Fabricio de Carvalho et al.
INTERNATIONAL JOURNAL OF CANCER (2009)
Epigenetic Cross-Talk between DNA Methylation and Histone Modifications in Human Cancers
Yutaka Kondo
YONSEI MEDICAL JOURNAL (2009)
Automethylation of G9a and its implication in wider substrate specificity and HP1 binding
Hang Gyeong Chin et al.
NUCLEIC ACIDS RESEARCH (2007)
5-Azacytidine, a DNA methyltransferase inhibitor, induces ATR-mediated DNA double-strand break responses, apoptosis, and synergistic cytotoxicity with doxorubicin and bortezomib against multiple myeloma cells
Tanyel Kiziltepe et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Targeted therapy of multiple myeloma based upon tumor-microenvironmental interactions
Kenneth C. Anderson
EXPERIMENTAL HEMATOLOGY (2007)
FOXO4 transcriptional activity is regulated by monoubiquitination and USP7/HAUSP
Armando van der Horst et al.
NATURE CELL BIOLOGY (2006)
Procainamide is a specific inhibitor of DNA methyltransferase 1
BH Lee et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Molecular pathogenesis and a consequent classification of multiple myeloma
PL Bergsagel et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Protein S-nitrosylation:: Purview and parameters
DT Hess et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2005)
Dysregulation of DNA repair pathways in a transforming growth factor α/c-myc transgenic mouse model of accelerated hepatocarcinogenesis
K Hironaka et al.
LABORATORY INVESTIGATION (2003)
ATM phosphorylates histone H2AX in response to DNA double-strand breaks
S Burma et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Vascular endothelial growth factor triggers signaling cascades mediating multiple myeloma cell growth and migration
K Podar et al.
BLOOD (2001)
Share Paper
